Jayantha Ratnayake

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Stephen Chia, Tamas Hickish, V. Harvey et al. · Annals of Oncology · 2013 · 1.3K citations

Medicine, Oncology, Pharmacology +14

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca et al. · The Lancet Oncology · 2015 · 363 citations

Medicine, Oncology, Pharmacology +14

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification

Eric Van Cutsem, Yu Jeong Bang, Wasat Mansoor et al. · Annals of Oncology · 2017 · 187 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

Sarah Hrebien, Valentina Citi, Isaac García-Murillas et al. · Annals of Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17